drug
as of 2026-07-01SM-13496 80mg
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Sumitomo Pharmaceuticals America
1 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
1
A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
NCT01614899Phase 3Completed
KOLs & investigators
1
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
indication
indication
indication
KOL
person